Georgia Sofia Karachaliou

Dr. Georgia Sofia Karachaliou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
DSDimitrios Schizas
Dimitrios Schizas
LNLeon Naar
Leon Naar
Diamantis I. TsilimigrasDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
Ioannis KatsarosIoannis Katsaros
Ioannis Katsaros
DMDimitrios Moris
Dimitrios Moris
Chemotherapy resistance is a rising concern in Gastric Cancer (GC) and has led to the investigation of various cellular compounds. Α functional equilibrium of histone acetylation and deacetylation was discovered in all cells, regulated by Histone Acetyltransferases and Deacetylases (HDACs), controlling chromatin coiling status and changing gene expression appropriately. In accordance with recent research, this equilibrium can be dysregulated in cancer cells aiding in the process of carcinogenesis and tumor progression by altering histone and non-histone proteins affecting gene expression, cell cycle control, differentiation, and apoptosis in various malignancies. In addition, increased HDAC expression in GC cells has been associated with increased stage, tumor invasion, nodal metastases, increased distant metastatic potential, and decreased overall survival. HDAC inhibitors could be used as treatment regimens for GC patients and could develop important synergistic interactions with chemotherapy drugs. The aim of this article is to review the molecular identity and mechanism of action of HDAC inhibitors, as well as highlight their potential utility as anti-cancer agents in GC.

14 February 2024 in Hepatology Communications
Verified
Journal Article
Open access
WMWilliam A. Murphy
William A. Murphy
ADAnna Mae Diehl
Anna Mae Diehl
MLMatthew Shane Loop
Matthew Shane Loop
DFDong Fu
Dong Fu
CGCynthia D. Guy
Cynthia D. Guy
KBKim L. R. Brouwer
Kim L. R. Brouwer
Background: NAFLD is highly prevalent with limited treatment options. Bile acids (BAs) increase in the systemic circulation and liver during NAFLD progression. Changes in plasma membrane localization and zonal distribution of BA transporters can influence transport function and BA homeostasis. However, a thorough characterization of how NAFLD influences these factors is currently lacking. This study aimed to evaluate the impact of NAFLD and the accompanying histologic features on the functional capacity of key hepatocyte BA transporters across zonal regions in human liver biopsies. Methods: A novel machine learning image classification approach was used to quantify relative zonal abundance and plasma membrane localization of BA transporters (bile salt export pump [BSEP], sodium-taurocholate cotransporting polypeptide, organic anion transporting polypeptide [OATP] 1B1 and OATP1B3) in non-diseased (n = 10), NAFL (n = 9), and NASH (n = 11) liver biopsies. Based on these data, membrane-localized zonal abundance (MZA) measures were developed to estimate transporter functional capacity. Results: NAFLD diagnosis and histologic scoring were associated with changes in transporter membrane localization and zonation. Increased periportal BSEPMZA (mean proportional difference compared to non-diseased liver of 0.090) and decreased pericentral BSEPMZA (−0.065) were observed with NASH and also in biopsies with higher histologic scores. Compared to Non-diseased Liver, periportal OATP1B3MZA was increased in NAFL (0.041) and NASH (0.047). Grade 2 steatosis (mean proportional difference of 0.043 when compared to grade 0) and grade 1 lobular inflammation (0.043) were associated with increased periportal OATP1B3MZA. Conclusions: These findings provide novel mechanistic insight into specific transporter alterations that impact BA homeostasis in NAFLD. Changes in BSEPMZA likely contribute to altered BA disposition and pericentral microcholestasis previously reported in some patients with NAFLD. BSEPMZA assessment could inform future development and optimization of NASH-related pharmacotherapies.

10 June 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
GKGeorgia Sofia Karachaliou
Georgia Sofia Karachaliou
ASAyako Suzuki
Ayako Suzuki
VPVaishali A. Patel
Vaishali A. Patel
LBLori A. Bastian
Lori A. Bastian
ADAnna Mae Diehl
Anna Mae Diehl
YWYing Wang
Ying Wang

1 January 2024 in Clinical Liver Disease
Verified
Journal Article
Closed access
GKGeorgia Sofia Karachaliou
Georgia Sofia Karachaliou
ASAyako Suzuki
Ayako Suzuki
Export

1 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
GKGeorgia Sofia Karachaliou
Georgia Sofia Karachaliou
APAmy M. Perkins
Amy M. Perkins
CDChad Dorn
Chad Dorn
RRRuth Madeleine Reeves
Ruth Madeleine Reeves
TATimothy Arnold
Timothy Arnold
ASAyako Suzuki
Ayako Suzuki
Background: Statins have been associated with a reduced risk of primary liver cancer (PLC), primarily hepatocellular carcinoma (HCC). However, the optimal use for effective protection and whether benefits vary by patient characteristics remain unclear. We evaluated the association between statin use and PLC risk in metabolic-dysfunction-associated steatotic liver disease (MASLD), considering cumulative exposure and potential effect modifiers. Methods: We conducted a retrospective cohort study using the Veteran Affairs electronic health records. Patients with chronically elevated liver enzymes and metabolic dysfunction, without other chronic liver diseases, were identified between 2007 and 2009 and followed through 2019 for incident PLC. Statin exposure was assessed at baseline and during the follow-up, with dose standardization by LDL-lowering potency (simvastatin-equivalent units). Time to PLC was analyzed using Cox models adjusted for covariates, considering potential interactions. Results: Among 329,577 patients (92% male; median age 62 years), 0.82% developed PLC (median follow-up of 9.7 years). Baseline statin use showed a significantly lower PLC risk (adjusted hazard ratio 0.64; 95% CI, 0.57–0.71; p < 0.0001). No significant interaction was observed with age, sex, metabolic syndrome, or cirrhosis. Higher cumulative statin exposure demonstrated a dose-dependent risk reduction, remaining significant at simvastatin-equivalent doses > 15,561 mg annually after accounting for incident cirrhosis. Atorvastatin/rosuvastatin use provided comparable protection, despite different lipophilicity, and demonstrated stronger effects than others. Conclusions: In MASLD, statin therapy was associated with a dose-dependent PLC risk reduction. High-intensity therapy (simvastatin-equivalent > 40 mg daily) conferred substantial protection regardless of age, sex, insulin resistance, or cirrhosis, supporting a potential statin-based PLC chemoprevention in MASLD.